Early-phase clinical studies—including MEDIOLA, TOPACIO, and KEYLYNK-007—have confirmed the feasibility and safety of combining PARP inhibitors with immune checkpoint blockade, particularly in BRCA1/2-mutated breast, ovarian, and prostate cancers [101,121]. The gene discussed is BRCA1; the disease is prostate cancer.